Compare PFBC & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFBC | PCRX |
|---|---|---|
| Founded | 1991 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2010 |
| Metric | PFBC | PCRX |
|---|---|---|
| Price | $88.71 | $22.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $102.67 | $35.33 |
| AVG Volume (30 Days) | 67.6K | ★ 739.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.16 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $2.94 | $9.77 |
| Revenue Next Year | $8.31 | $9.71 |
| P/E Ratio | ★ $8.85 | $142.97 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $73.08 | $18.80 |
| 52 Week High | $103.05 | $27.99 |
| Indicator | PFBC | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.77 | 47.57 |
| Support Level | $80.74 | $20.41 |
| Resistance Level | $94.25 | $23.82 |
| Average True Range (ATR) | 2.53 | 1.00 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 40.43 | 43.41 |
Preferred Bank is a commercial bank located in California. Its products and services are divided into Personal Banking, Business Banking, and Commercial Banking which includes Checking accounts, Savings accounts, CDs, Loans and Credit, Electronic banking, and Treasury Management. It provides personalized deposit services, real estate finance, commercial loans, and trade finance credit facilities to small and mid-sized businesses and their owners, entrepreneurs, real estate developers and investors, professionals, and high-net-worth individuals. The bank generates a majority of its revenue from Southern and Northern California and Flushing.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.